Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL2586200 | 0.94 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| D-Histidine SCHEMBL11606906 | 0.94 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL2586203 | 0.94 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL27902238 | 0.94 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL28801818 | 0.93 | — | — | |
| Histidine SCHEMBL3194028 | 0.93 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL5058220 | 0.90 | ALOX15 (0.38) | CYP3A4SLC7A5CTSC | |
| Histidine SCHEMBL3088582 | 0.89 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL3490081 | 0.89 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL1675273 | 0.89 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275416-A1 | Affinity marker for purification of proteins | GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE) | 2007-11-29 | — | — | US | claimed |
| EP-4247957-A1 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | MedImmune Limited (GB) | 2023-09-27 | — | — | EP | disclosed |
| CN-116670268-A | Fusion proteins comprising E2 ubiquitin or ubiquitin-like conjugation domains and targeting domains for specific protein degradation | 免疫医疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022106869-A1 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | MEDIMMUNE LIMITED (GB) | 2022-05-27 | — | — | WO | disclosed |
| US-20070275416-A1 | Affinity marker for purification of proteins | GSF-FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE) | 2007-11-29 | — | — | US | disclosed |